Biomea Fusion To Host Conference Call And Webcast On Wednesday, October 30 At 4:30 Pm ET To Announce Lead Clinical Candidate, BMF-650, A Oral Small-Molecule GLP-1 Receptor Agonist And Preclinical Data Combining BMF-219 With A GLP-1 RA-Based Therapy
Biomea Fusion To Host Conference Call And Webcast On Wednesday, October 30 At 4:30 Pm ET To Announce Lead Clinical Candidate, BMF-650, A Oral Small-Molecule GLP-1 Receptor Agonist And Preclinical Data Combining BMF-219 With A GLP-1 RA-Based Therapy
Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically defined cancers, today announced that it will host a conference call and webcast on Wednesday, October 30th at 4:30 pm ET to announce our lead clinical candidate, BMF-650 – a next-generation, potent, selective, oral small-molecule GLP-1 receptor agonist (GLP-1 RA) and to share results of preclinical studies investigating the synergistic benefits of combining BMF-219 with a GLP-1 RA-based therapy.
Biomea Fusion, Inc.（"Biomea"）（納斯達克:BMEA），一家臨床階段的生物製藥公司，致力於發現和開發口服共價小分子，用於治療和改善患有糖尿病、肥胖和基因定義癌症的患者的生活。今天宣佈將於美國東部時間10月30日下午4:30舉行電話會議和網絡直播，宣佈我們的首席臨床候選藥BMF-650——一種下一代、強效、選擇性的口服小分子GLP-1受體激動劑（GLP-1 RA），並分享關於將BMF-219與GLP-1 RA爲基礎的療法結合的臨床前研究結果。
譯文內容由第三人軟體翻譯。
